Literature DB >> 22632641

Visceral leishmaniasis.

Johan van Griensven1, Ermias Diro.   

Abstract

Visceral leishmaniasis (VL) is a vector-borne parasitic disease targeting tissue macrophages. It is among the most neglected infectious diseases. Classical manifestations of VL include chronic fever, hepatosplenomegaly, and pancytopenia. Most cases can be detected through serologic and molecular testing. Although therapy has historically relied on antimonials, newer therapeutic options include conventional or liposomal amphotericin B, paromomycin and miltefosine. Coinfection with human immunodeficiency virus (HIV) is increasingly reported and comes with additional diagnostic and therapeutic challenges. This article provides an up-to-date clinical review of VL focusing on clinical presentation, diagnosis, management, and issues related to HIV coinfection.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632641     DOI: 10.1016/j.idc.2012.03.005

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  68 in total

1.  The sera from adult patients with suggestive signs of autoimmune diseases present antinuclear autoantibodies that cross-react with Leishmania infantum conserved proteins: crude Leishmania histone and Soluble Leishmania antigens [corrected].

Authors:  Sami Lakhal; Meriem Benabid; Ines Ben Sghaier; Jihen Bettaieb; Aïda Bouratbine; Yousr Galai
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis.

Authors:  A C Vallur; A Hailu; D Mondal; C Reinhart; H Wondimu; Y Tutterrow; H W Ghalib; S G Reed; M S Duthie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-19       Impact factor: 3.267

Review 3.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

4.  Lactate dehydrogenase (LD), alkaline phosphatase (ALP) isoenzymatic patterns in Iraqi children with visceral leishmaniasis before and after treatment with stibogluconate.

Authors:  Jasim Hameed Taher; Yassir Mustafa Kamal Al-Mulla Hummadi; Nada Muhammed Taha Al-Bashir; Ali Shaalan Al-Araji
Journal:  J Parasit Dis       Date:  2014-06-22

5.  Diagnosis of Visceral Leishmaniasis Using Peripheral Blood Microscopy in Ethiopia: A Prospective Phase-III Study of the Diagnostic Performance of Different Concentration Techniques Compared to Tissue Aspiration.

Authors:  Ermias Diro; Cedric P Yansouni; Yegnasew Takele; Bewketu Mengesha; Lutgarde Lynen; Asrat Hailu; Johan van Griensven; Marleen Boelaert; Philippe Büscher
Journal:  Am J Trop Med Hyg       Date:  2016-10-31       Impact factor: 2.345

6.  Cutaneous and visceral leishmaniasis during anti-TNFα therapy.

Authors:  Claudio Guarneri; Valentina Bevelacqua; James W Patterson; Georgi Tchernev
Journal:  Wien Med Wochenschr       Date:  2016-11-10

7.  Late diagnosis: a factor associated with death from visceral leishmaniasis in elderly patients.

Authors:  Marta Driemeier; Polliana Alvarenga de Oliveira; Angelita Fernandes Druzian; Laís Ferreira Lopes Brum; Elenir Rose Jardim Cury Pontes; Maria Elizabeth Cavalheiros Dorval; Anamaria Mello Miranda Paniago
Journal:  Pathog Glob Health       Date:  2015-08-10       Impact factor: 2.894

8.  Biomarkers for intracellular pathogens: establishing tools as vaccine and therapeutic endpoints for visceral leishmaniasis.

Authors:  A C Vallur; M S Duthie; C Reinhart; Y Tutterrow; S Hamano; K R H Bhaskar; R N Coler; D Mondal; S G Reed
Journal:  Clin Microbiol Infect       Date:  2013-11-18       Impact factor: 8.067

9.  Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.

Authors:  Anny Fortin; Diana P Caridha; Susan Leed; Franklyn Ngundam; Jenell Sena; Tom Bosschaerts; Sandi Parriott; Mark R Hickman; Thomas H Hudson; Max Grogl
Journal:  PLoS Negl Trop Dis       Date:  2014-09-11

10.  Monitoring resistance to Bacillus thuringiensis subsp. israelensis in the field by performing bioassays with each Cry toxin separately.

Authors:  Guillaume Tetreau; Renaud Stalinski; Jean-Philippe David; Laurence Després
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.